Kiadis Pharma has presented one-year follow-up data from a Phase II study in leukaemia patients (n=23) at the 58th meeting of the American Society of Hematology (ASH) in San Diego, US. Patients were administered ATIR101 after a haematopoietic stem cell transplant (HSCT) from a partially matching donor. The primary endpoint of transplant-related mortality (TRM) and secondary endpoint overall survival (OS) for patients receiving HSCT+ATIR101 were significantly higher than patients receiving HSCT alone from an observational control group. We are encouraged to see the low incidence of relapse in the ATIR101 arm in this high-risk patient population. Our valuation is €383.2m or €27.4 per share.

Continue reading

This version is programmatically created by Responsive Labs and qualified in its entirety to the original PDF.

Powered by Responsive Labs